CAR-T cell persistence in the treatment of leukemia and lymphoma. Issue 11 (19th September 2021)

• Record Type: Journal Article
• Authors: Gupta, Arjun; Gill, Saar
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 11(2021)
• Page Start: 2587
• Page End: 2599
• Publication Date: 2021-09-19
• Subjects: Chimeric antigen receptor (CAR) T cell -- persistence -- CD19 -- leukemia -- lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1913146
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Chimeric antigen receptor (CAR) T cells have emerged as a powerful therapeutic modality for cancer. Following encouraging clinical results, autologous anti-CD19 CAR-T cells first secured regulatory approval from the U.S. Food and Drug Administration in 2017 for the treatment of pediatric B cell acute lymphoblastic leukemia and for diffuse large B cell lymphoma (DLBCL), followed recently by mantle cell lymphoma. While long-term immunosurveillance is among the most important requirements for durable remissions in leukemia and a major potential benefit of immunotherapy, the exact determinants of CAR-T cell persistence remain elusive. Furthermore, it is less clear that long-term persistence is required for durable remission in lymphoma. In this review, we aim to describe the factors governing CAR-T cell persistence as well as unique approaches to exert control over engineered lymphocyte populations post-infusion. Additionally, we explore potential risks and associated clinical considerations arising from prolonged surveillance by highly reactive cytotoxic T lymphocytes.